← ANALYST RATINGS · TIPRANKS
Abbott Laboratories (ABT): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $124, the highest $135, the lowest $112. The average is +17.8% from the last price of $105.
Analyst ratings 27
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $135 | Buy | +28.7% | Reiterated | 16.10.26on TipRanks 08:30 | +1.3% | ↗ |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $114 → $115+0.9% | Buy | +9.6% | Reiterated | 16.10.26on TipRanks Oct 15 22:05 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $114 → $115+0.9% | Buy | +9.6% | Reiterated | 14.10.26on TipRanks 15:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $114 → $115+0.9% | Buy | +9.6% | Reiterated | 14.10.26on TipRanks 15:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $111 → $112+0.9% | Hold | +6.8% | Reiterated | 14.10.26on TipRanks 15:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $113 → $114+0.9% | Buy | +8.7% | Reiterated | 14.10.26on TipRanks 15:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $115 → $116+0.9% | Buy | +10.6% | Reiterated | 14.10.26on TipRanks 15:05 | — | |
| Unknown Analyst | Leerink Partners | — | Hold | — | Reiterated | 12.10.26on TipRanks Oct 13 11:05 | +2.3%next day +0.8% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $120 | Buy | +14.4% | Initiated | 07.10.26on TipRanks 03:55 | +0.8%next day +0.2% · 5 days +5.3% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $125 | Buy | +19.2% | Reiterated | 05.10.26on TipRanks 07:21 | +2.0%next day −2.5% · 5 days +1.3% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $112 | Buy | +6.8% | Reiterated | 05.10.26on TipRanks 07:16 | +2.0%next day −2.5% · 5 days +1.3% | ↗ |
| Ed Ridley-Day★★★★★★★★★★#5780 · hits 54% · avg +8.0% | Rothschild & Co Redburn | $119 → $127+6.7% | Buy | +21.1% | Upgrade | 02.10.26on TipRanks 05:07 | +0.1%next day +2.0% · 5 days +1.0% | ↗ |
| Name not given | — | $130 | Buy | +23.9% | Reiterated | 01.10.26on TipRanks Oct 2 21:45 | −2.3%next day +0.1% · 5 days +0.6% | ↗ |
| Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% | Bank of America Securities | $115 | Buy | +9.6% | Reiterated | 01.10.26on TipRanks Oct 2 05:07 | −2.3%next day +0.1% · 5 days +0.6% | ↗ |
| Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% | J.P. Morgan | — | Buy | — | Reiterated | 01.09.26on TipRanks 09:15 | −0.6%next day +1.0% · 5 days −3.5% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $118 | Buy | +12.5% | Reiterated | 26.08.26on TipRanks 07:35 | −1.8%next day −2.9% · 5 days −3.1% | ↗ |
| Matthew Taylor★★★★★★★★★★#1367 · hits 55% · avg +7.2% | Jefferies | $135 | Buy | +28.7% | Reiterated | 21.08.26on TipRanks 12:16 | +1.8%next day +0.3% · 5 days −4.0% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Buy | — | Reiterated | 21.08.26on TipRanks 04:55 | +1.8%next day +0.3% · 5 days −4.0% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $134 | Buy | +27.8% | Reiterated | 20.08.26on TipRanks Aug 21 06:27 | +0.6%next day +1.8% · 5 days −3.3% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | $130 | Buy | +23.9% | Upgrade | 13.08.26on TipRanks 06:10 | −0.4%next day +0.2% · 5 days +4.5% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $135 → $125−7.4% | Buy | +19.2% | Assigned | 28.07.26on TipRanks 08:22 | +2.4%next day +2.2% · 5 days −5.8% | ↗ |
| Jayson Bedford★★★★★★★★★★#819 · hits 60% · avg +8.6% | Raymond James | — | Buy | — | Reiterated | 17.07.26on TipRanks Jul 19 10:35 | +2.9%next day +1.1% · 5 days +3.0% | ↗ |
| Shagun Singh Chadha★★★★★★★★★★#9557 · hits 48% · avg −0.4% | RBC Capital | $130 | Buy | +23.9% | Reiterated | 16.07.26on TipRanks Jul 17 07:06 | +11.3%next day +2.9% · 5 days +3.6% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $120 → $112−6.7% | Buy | +6.8% | Reiterated | 06.07.26on TipRanks 08:45 | −0.6%next day +0.7% · 5 days −3.4% | ↗ |
| David Rescott★★★★★★★★★★#3448 · hits 49% · avg +5.1% | Robert W. Baird | $121 | Buy | +15.4% | Initiated | 30.06.26on TipRanks 16:25 | +1.7%next day +3.6% · 5 days +1.6% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $121 → $113−6.6% | Buy | +7.7% | Reiterated | 31.05.26on TipRanks Jun 1 08:35 | +2.3%next day −1.1% · 5 days +5.6% | ↗ |
| Narumi Nakagiri★★★★★★★★★★#5254 · hits 64% · avg +9.1% | Daiwa | $113 → $92.00−18.6% | Hold | −12.3% | Downgrade | 21.04.26on TipRanks 20:30 | −2.1%next day +1.2% · 5 days −0.5% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $125 → $115−8.0% | Hold | +9.6% | Reiterated | 20.04.26on TipRanks 08:15 | −0.6%next day −2.8% · 5 days −4.2% | ↗ |
| Suraj Kalia★★★★★★★★★★#1646 · hits 50% · avg +6.8% | Oppenheimer | $132 → $115−12.9% | Buy | +9.6% | Reiterated | 17.04.26on TipRanks 21:15 | −0.6%next day −2.8% · 5 days −4.2% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | $145 → $120−17.2% | Buy | +14.4% | Reiterated | 17.04.26on TipRanks 07:10 | +0.2%next day −0.6% · 5 days −6.4% | ↗ |
| Rick Wise★★★★★★★★★★#7800 · hits 51% · avg +0.1% | Stifel Nicolaus | $145 → $120−17.2% | Buy | +14.4% | Assigned | 17.04.26on TipRanks 06:55 | +0.2%next day −0.6% · 5 days −6.4% | ↗ |
| Unknown Analyst | Erste Group | — | Hold | — | Reiterated | 01.04.26on TipRanks Apr 2 23:30 | −1.0%next day +0.4% · 5 days −3.4% | ↗ |
| Lee Hambright★★★★★★★★★★#10167 · hits 49% · avg −1.6% | Bernstein | $154 → $125−18.8% | Buy | +19.2% | Reiterated | 23.01.26on TipRanks 07:25 | −1.1%next day +0.7% · 5 days +1.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Abbott Laboratories
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $125 at a price of $98.83 (+26.1%); now: $126 at $105 (+19.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 19 | 26 | 24 | 30 | 24 | 17 |
| Hold | 3 | 3 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 21.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.42 (from $1.40 to $1.44). Last quarter: $1.31.
Sales
Next quarter’s sales estimate — $13.0B (from $12.9B to $13.1B). Last quarter: $12.6B.
Best top-analyst consensus in the sector · Healthcare
About Abbott Laboratories
- CEO: Robert Ford
- Employees: 115,000
- 100 Abbott Park Road, Abbott Park, IL, 60064-6400, US
- www.abbott.com
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm man
Data from the stock’s TipRanks forecast page, read 13 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗